These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9495606)

  • 41. A biomodal distribution of plasma HVA/MHPG in the psychoses.
    Ottong SE; Garver DL
    Psychiatry Res; 1997 Mar; 69(2-3):97-103. PubMed ID: 9109177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Homovanillic acid in caudate and pre-frontal cortex following acute and chronic neuroleptic administration.
    Bowers MB; Hoffman FJ
    Psychopharmacology (Berl); 1986; 88(1):63-5. PubMed ID: 2868484
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma homovanillic acid as a predictor of response to neuroleptics.
    Davila R; Manero E; Zumarraga M; Andia I; Schweitzer JW; Friedhoff AJ
    Arch Gen Psychiatry; 1988 Jun; 45(6):564-7. PubMed ID: 3377643
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma homovanillic acid levels and subtyping of schizophrenia.
    Chang WH; Chen TY; Lee CF; Hung JC; Hu WH; Yeh EK
    Psychiatry Res; 1988 Mar; 23(3):239-44. PubMed ID: 3387499
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Homovanillic acid in the cerebrospinal fluid: patterns of response after four weeks of neuroleptic treatment.
    Sharma RP; Javaid JI; Janicak PG; Davis JM; Faull K
    Biol Psychiatry; 1993 Aug; 34(3):128-34. PubMed ID: 8104508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of neuroleptic-resistant mania and schizoaffective disorders.
    De Beaurepaire R
    Am J Psychiatry; 1992 Nov; 149(11):1614-5. PubMed ID: 1357993
    [No Abstract]   [Full Text] [Related]  

  • 47. Elevated plasma monoamine metabolites in eating disorders.
    Bowers MB; Mazure CM; Greenfeld DG
    Psychiatry Res; 1994 Apr; 52(1):11-5. PubMed ID: 8047617
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum.
    Garver DL; Holcomb JA; Christensen JD
    J Clin Psychiatry; 2000 Dec; 61(12):964-72; quiz 973. PubMed ID: 11206608
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
    Crespo-Facorro B; Rodríguez-Sánchez JM; Pérez-Iglesias R; Mata I; Ayesa R; Ramirez-Bonilla M; Martínez-Garcia O; Vázquez-Barquero JL
    J Clin Psychiatry; 2009 Apr; 70(5):717-29. PubMed ID: 19389335
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Psychotic patients with increased plasma HVA and MHPG or increased HVA alone.
    Bowers MB
    Biol Psychiatry; 1993 Oct; 34(8):584-6. PubMed ID: 8274591
    [No Abstract]   [Full Text] [Related]  

  • 53. Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients.
    Rapaport MH; Wolkowitz O; Kelsoe JR; Pato C; Konicki PE; Pickar D
    Neuropsychopharmacology; 1993 Sep; 9(2):111-5. PubMed ID: 8105790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biological correlates of the congruence and incongruence of psychotic symptoms in patients with type 1 bipolar disorder.
    Basterreche N; Dávila R; Zumárraga M; Arrúe A; González-Torres MA; Zamalloa MI; Anguiano JB; Guimón J
    Neuropsychobiology; 2008; 58(3-4):111-7. PubMed ID: 18997477
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients.
    Pickar D; Breier A; Kelsoe J
    Ann N Y Acad Sci; 1988; 537():339-46. PubMed ID: 2904783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
    Coley KC; Carter CS; DaPos SV; Maxwell R; Wilson JW; Branch RA
    J Clin Psychiatry; 1999 Dec; 60(12):850-6. PubMed ID: 10665632
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistence of cyclicity of the plasma dopamine metabolite, homovanillic acid, in neuroleptic treated schizophrenic patients.
    Davila R; Zumarraga M; Andia I; Friedhoff AJ
    Life Sci; 1989; 44(16):1117-21. PubMed ID: 2565009
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Brain contribution to the haloperidol-induced increase in plasma homovanillic acid.
    Kendler KS; Heninger GR; Roth RH
    Eur J Pharmacol; 1981 May; 71(2-3):321-6. PubMed ID: 7250191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Specificity of plasma HVA response to dexamethasone in psychotic depression.
    Wolkowitz OM; Doran A; Breier A; Roy A; Pickar D
    Psychiatry Res; 1989 Aug; 29(2):177-86. PubMed ID: 2798596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.
    Yoshimura R; Ueda N; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):256-61. PubMed ID: 20218790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.